[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cgvhd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cgvhd":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,65,87,109,135,156,185,210,240],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100567095","phase-2-axatilimab-in-combination-with-extracorporeal-photopheresis-ecp-in-chronic-graft-versus-host-disease-100567095",false,"NCT06663722","Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease","A Phase II b Study of Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease","Inclusion Criteria:\n\n1. Recipient of allogeneic hematopoietic cell transplantation (HCT).\n2. Age greater or equal to 12.\n3. Chronic GVHD per 2014 National Institutes of Health Consensus Criteria (NCC) (Jagasia et al. 2015) or overlap syndrome requiring new therapy in patients with at least 2 prior lines of therapy, steroid refractoriness, or steroid dependence:\n\n   1. Prior systemic lines of therapy may include corticosteroids, calcineurin inhibitor (CNI) or sirolimus, or other systemic immunosuppressive agent such as ruxolitinib, belumosudil, or ibrutinib. GVHD prophylaxis does not count as a prior line of therapy.\n   2. Steroid refractory is defined as any of the following criteria:\n\n      * i. Manifestations progress despite the use of ≥ 1 mg\u002Fkg\u002Fday prednisone for at least 1 week\n      * ii. Manifestations persist without improvement despite treatment with ≥ 0.5 mg\u002Fkg\u002Fday or 1 mg\u002Fkg every other day for at least four weeks.\n      * iii. Recurrence after a CR, or\n      * iv. Progression after a PR.\n   3. Steroid dependence is defined as inability to control cGVHD symptoms while tapering prednisone below 0.25 mg\u002Fkg\u002Fday on at least two occasions separated by at least 8 weeks. There must be evidence of clinically active cGVHD.\n4. For patients receiving approved or commonly used agents, all GVHD systemic treatments should be discontinued except for corticosteroids and drugs being continued from GVHD prophylaxis at screening.\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0-3 as assessed at Screening.\n6. Platelet count \\> 50,000 platelets\u002FμL and absolute neutrophil count \\> 1,000 cells\u002FμL as measured at Screening.\n7. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN), unless attributed to presumed cGVHD as measured at Screening.\n8. Stable dose of corticosteroids for at least 14 days prior to treatment.\n9. Sexually mature individuals must use contraception as described in Section 4.12. For individuals less than 18 years of age, sexual maturity will be determined as per treating pediatrician.\n\nExclusion Criteria:\n\n1. Pregnancy or breast-feeding.\n2. Active relapse of underlying malignancy.\n3. History or the presence of interstitial pneumonitis or drug-related pneumonitis.\n4. Active gastrointestinal (GI) bleeding.\n5. Inability to tolerate volume shifts associated with ECP (e.g., inadequate renal, hepatic, pulmonary and cardiac function (ejection fraction (EF) \\\u003C 40%) per Investigator discretion.\n6. History of myositis.\n7. History of splenectomy.\n8. History of pancreatitis.\n9. History of other malignancy (within 3 years of Screening) unless treated with curative intent and approved by Principal Investigator (PI).\n10. Significant, uncontrolled, or active comorbid conditions or are unable to adhere to the study requirements.\n11. Acquired Immune Deficiency Syndrome (AIDS) or active hepatitis B (Hep B) or active hepatitis C (Hep C) infection.\n12. Prior colony-stimulating factor-1 (CSF-1R) targeted therapies.\n13. Prior history of ECP treatment failure or intolerance.\n14. Intolerance to methoxsalen, heparin, or citrate products.\n15. Patients with aphakia due to risk of increased retinal damage or photosensitive disease (albinism, systemic lupus erythematosus, porphyria).\n16. Lack of stable IV access. Acceptable forms include central venous catheter, peripherally inserted central catheter (PICC), or peripheral IV line per institutional guidelines.\n17. Insurance denial of coverage for the ECP procedure.","ALL","12 Years",{"count":19,"type":20},49,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to see whether giving participants a combination treatment of Axatilimab and Extracorporeal Photopheresis (ECP) is effective against chronic Graft-versus-Host Disease (cGVHD).",[26,27],"Chronic Graft Versus Host Disease","cGVHD","RECRUITING","2026-06-18",{"date":31,"type":32},"2026-06-22","ACTUAL",{"date":34,"type":32},"2025-05-05",{"date":36,"type":20},"2030-05-05",{"name":38,"class":39},"University of Miami","OTHER",3,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":4},"100544087","phase-4-efficacy-and-safety-of-anti-cd25-rhmab-in-the-treatment-of-steroid-refractory-cgvhd-100544087","NCT06364319","Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD","Study on the Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease (cGVHD) of the Liver Following Allogeneic Hematopoietic Stem Cell Transplantation.","Inclusion Criteria:\n\n1. Age 16 and 65 years\n2. Received allogeneic hematopoietic stem cell transplantation\n3. Developed chronic GVHD in the liver after transplantation\n4. Ineffective prednisone treatment prior to screening\n5. Received ≤4 lines of systemic therapy prior to screening\n6. After informed consent, the patient agreed to receive anti-CD25 rhMAb treatment\n\nExclusion Criteria:\n\n1. Elevation of bilirubin, ALT, or alkaline phosphatase due to reasons other than chronic GVHD\n2. No prior treatment with prednisone\n3. Overlap syndrome\n4. Uncontrolled active infection\n5. Organ failure\n6. Early progression or recurrence of hematologic diseases\n7. Allergy to anti-CD25 rhMAb\n8. Received other interleukin-2 receptor monoclonal antibody treatment due to various reasons within one month after transplantation\n9. Participated in other clinical studies within one month","16 Years","65 Years",{"count":51,"type":20},30,[53],"PHASE4","The study plan aims to include patients who have been diagnosed with steroid-refractory chronic GVHD in the liver following allogeneic hematopoietic stem cell transplantation. After obtaining informed consent, the patients will receive a treatment regimen consisting of the Anti-CD25 rhMAb in combination with prednisone, cyclosporine, and ruxolitinib.The objective is to assess the effectiveness and safety of Anti-CD25 rhMAb in the treatment of severe chronic GVHD affecting the liver.",[27],"NOT_YET_RECRUITING","2026-06-16",{"date":29,"type":32},{"date":60,"type":20},"2026-07-15",{"date":62,"type":20},"2028-06-30",{"name":64,"class":39},"Peking University People's Hospital",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":72,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":4},"100630164","phase-1-il6-receptor-inhibitor-iwith-belumosudil-for-the-treatment-of-belumosudil-refractory-cgvhd-100630164","NCT07484113","IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD","IL6-receptor Inhibitor in Combination With Belumosudil for the Treatment of Belumosudil-refractory Chronic Graft-versus-host Disease (cGVHD)","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Active cGVHD and currently receiving belumosudil with inadequate response (defined as disease progression at any time or failure to achieve at least a partial response after a minimum of 3 months of belumosudil therapy, and for whom the treating physician believes a new systemic therapy is required).\n3. Persistent cGVHD manifestations and systemic therapy indicated.\n4. Karnofsky Performance Score of ≥ 60.\n\n   Laboratory Parameters:\n5. Absolute neutrophil count ≥ 1.5 x 109\u002FL\n6. Platelet count ≥ 50 x 109\u002FL\n7. ALT and AST \\\u003C 1.5 × ULN\n8. Total bilirubin ≤ 1.5 × ULN\n9. Glomerular filtration rate (GFR) ≥ 30 ml\u002Fmin\u002F1.73m2\n\n   General Criteria:\n10. Negative urine pregnancy test at screening for females of childbearing potential.\n11. Sexually active females of childbearing potential must agree to use two accepted methods of contraception during treatment and for 3 months after their last dose.\n12. Sexually active male subjects with female partners of childbearing potential must agree to use two accepted methods of contraception and refrain from sperm donation during treatment and for at least 3 months after their last dose.\n\n14\\. Ability to provide written informed consent (or consent from legally authorized representative). 15. Minimum weight of 63 kg\n\nExclusion Criteria:\n\n1. Not on a stable systemic cGVHD treatments for at least 2 weeks prior to screening. (Note: Concomitant corticosteroids, calcineurin inhibitors, sirolimus are allowed. Systemic investigational GVHD treatments are not permitted).\n2. Histological relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening.\n3. Current treatment with ibrutinib or ruxolitinib. Prior treatment is allowed with a washout of at least 1 week prior to randomization.\n\n   General Criteria:\n4. Pregnant or breastfeeding.\n5. History or other evidence of severe illness or any other conditions that would make the subject, in the opinion of the sponsor-investigator, unsuitable for the study (such as malabsorption syndromes, poorly controlled psychiatric disease or coronary artery disease).\n6. Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) or history of human immunodeficiency virus (HIV).\n7. Malignancy diagnosed within 3 years (other than malignancy for which transplant was performed), with the exception of:\n\n   1. Completely resected basal cell or squamous cell carcinoma of the skin\n   2. Carcinoma in situ of the cervix\n   3. Resected breast ductal carcinoma in situ\n   4. Prostate cancer with Gleason score \\\u003C6 and stable PSA over 12 months\n8. QTc(F) \\> 480 ms\n9. Sponsor-investigator deems subject unlikely to adhere to study procedures\u002Ftreatment.\n10. Investigational agent, device, or procedure within 28 days of first dose (or 5 half-lives, whichever longer).\n11. Active TB or a history of incompletely treated TB regardless of screening Quantiferon Result.","18 Years",{"count":5,"type":20},[75],"PHASE1","A single-center, Phase 1, open-label, investigator-initiated clinical trial evaluating the safety, tolerability, and preliminary efficacy of sarilumab (anti-IL-6R) monotherapy as a rescue in adult patients with belumosudil-refractory chronic graft-versus-host disease (cGVHD).",[27],"2026-06-10",{"date":80,"type":32},"2026-06-12",{"date":82,"type":20},"2026-07",{"date":84,"type":20},"2028-05",{"name":86,"class":39},"Stanford University",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":72,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100643278","phase-2-belumosudil-with-ruxolitnib-as-second-line-therapy-for-chronic-graft-versus-host-disease-cgvhd-after-steroid-failure-100643278","NCT07643025","Belumosudil With Ruxolitnib as Second Line Therapy for Chronic Graft Versus Host Disease (cGvHD) After Steroid Failure","A Phase 2 Study of Belumosudil Combined With Ruxolitinib as Second Line Therapy to Treat Chronic Graft Versus Host Disease (cGvHD) After Steroid Failure (BELRUX)","BELRUX","Inclusion Criteria:\n\n* 18 years of age or older at the time of enrollment.\n* Has previously been diagnosed with moderate to severe cGvHD OR mild cGvHD with high-risk features (defined as platelet counts \\\u003C 100 x 109\u002FL at screening).\n* Capable of providing informed consent.\n* Meets the criteria of steroid-refractory cGvHD after first line therapy at the time of enrollment, as follows:\n\n  * Lack of response or disease progression after prednisone ≥1 mg\u002Fkg\u002Fday for ≥1 week OR\n  * Disease persistence without improvement with prednisone \\>0.5 mg\u002Fkg\u002Fday or 1 mg\u002Fkg\u002Fevery other day for ≥4 weeks OR\n  * Increase in prednisone dose to \\>0.25 mg\u002Fkg\u002Fday after 2 unsuccessful attempts to taper the dose.\n* Taking a steroid dose at the time of enrollment that is \\\u003C0.5mg\u002Fkg\u002Fday of prednisone or equivalent.\n* Absolute neutrophil count ≥ 1.5 × 109\u002FL within 2 weeks (14 days) of enrollment.\n* Platelet count ≥ 50 × 109\u002FL within 2 weeks of enrollment.\n* ALT and AST ≤ 5 × ULN (\\\u003C7.5 x ULN if due to liver GvHD) within 2 weeks of enrollment.\n* Total bilirubin ≤ 1.5 × ULN within 2 weeks of enrollment.\n* Glomerular filtration rate (GFR) ≥ 30 mL\u002Fmin\u002F1.73 m2 using the MDRD-4 variable formula within 2 weeks of enrollment.\n* Female patients of childbearing potential will use 2 reliable methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study from the time of study enrollment until 3 months following the discontinuation of all study treatment and agree not to donate or cryopreserve eggs (ova, oocytes) for the purpose of reproduction during this period. Patients of childbearing potential are those who have not been surgically sterilized (i.e. have a documented hysterectomy, or documented bilateral salpingectomy, or documented bilateral oophorectomy) or have not been free from menses for \\> 2 years. For individuals with permanent infertility due to an alternate medical cause other than the above (e.g. Mullerian agenesis, androgen insensitivity, gonadal dysgenesis) investigator discretion should be applied to determining study entry eligibility. Male patients will use an adequate method of contraception for the course of the study from the time of enrollment to 3 months after discontinuation of all study treatment. These participants must refrain from donating or cryopreserving sperm, be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent or must agree to use contraception (a male condom and an additional highly effective contraceptive method as described in section 4.2.3) when having sexual intercourse with a woman of childbearing potential who is not currently pregnant.\n* Patients showing overlap syndrome with components of aGvHD at the time of enrollment are eligible to participate unless the acute component of their overlap syndrome is Grade 3 or 4.\n* Must be able and willing to comply with study procedures.\n\nExclusion Criteria:\n\n* Have never been treated with systemic steroids as first line therapy for cGvHD.\n* Receiving \\>0.5 mg\u002Fkg\u002Fday of prednisone or equivalent corticosteroids at the time of enrollment.\n* Has had prior treatment with a JAK inhibitor or ROCK2 inhibitor within 8 weeks of enrollment. Participants who received a JAK inhibitor for aGvHD are eligible only if they achieved CR or PR prior to screening.\n* Active uncontrolled bacterial, fungal, parasitic, or viral infection. Infections are considered controlled if appropriate therapy has been initiated and, at the time of screening, no signs of infection are present.\n* Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection that requires treatment, or is at risk for HBV reactivation (i.e., positive HBsAg) within 4 weeks of enrollment. Participants with negative HBsAg and positive total HBc antibody may be included if HBV DNA is undetectable at the time of screening. Participants who are positive for HCV antibody are eligible only if PCR is negative for HCV RNA. Participants whose immune status is unknown or uncertain must have results confirming immune status before enrollment. Prior serology results within 2 years are acceptable for determining eligibility.\n* Known active infection or history of human immunodeficiency virus (HIV).\n* Evidence of relapsed primary hematologic disease, or receipt of treatment for relapse after the allo-HCT was performed. Patients treated with Donor Lymphocyte Infusion (DLI) who have developed GvHD will not be excluded if the primary hematological disease has resolved.\n* Maintenance therapy for the primary hematologic disease started within 4 weeks before initiation of study treatment (Cycle 1 Day 1) or plans to start maintenance therapy after Day 1.\n* Participants on mechanical ventilation,requiring oxygen support or with a FEV1 \\\u003C 30%.\n* History or current diagnosis of cardiac disease indicating significant risk of safety for participation in the study, such as uncontrolled or significant cardiac disease, including any of the following:\n\n  1. Recent myocardial infarction (within 6 months of enrollment)\n  2. New York Heart Association Class III or IV congestive heart failure\n  3. Unstable angina (within 6 months of enrollment)\n  4. Clinically significant (symptomatic) cardiac arrhythmias (e.g. sustained ventricular tachycardia, and clinically significant second or third degree AV block without a pacemaker).\n* Uncontrolled hypertension, defined as blood pressure that remains above 130\u002F80 mmHg in spite of concurrent use of three antihypertensive agents of different classes.\n* Patients with known active CNS disease (malignant involvement of CNS).\n* Patients with active acute GvHD grade III-IV.\n* History or other evidence of severe illness or any other conditions that would make the patient, in the opinion of the treating Investigator, unsuitable for the study (such as malabsorption syndromes, poorly controlled psychiatric disease or coronary artery disease).\n* Known hypersensitivity to belumosudil, ruxolitinib or any of their excipients\n* Patients unable to swallow oral medications\n* Female participants who are pregnant or breastfeeding",{"count":96,"type":20},63,[23],"Chronic graft-versus-host disease (cGvHD) is a serious condition that can happen after a stem cell or bone marrow transplant. The donor's immune cells attack the patient's body, causing inflammation, pain, and damage to organs like the skin, liver, or lungs. For patients with moderate to severe cGvHD who don't improve with or can't tolerate standard front line therapy with steroids, there's a significant unmet need. Steroid-refractory cGvHD is hard to treat, with limited effective options, often leading to ongoing symptoms and reduced quality of life.\n\nThis Phase II study tests a new treatment combining two oral drugs, ruxolitinib and belumosudil, for these patients. Both drugs have helped cGvHD individually, but this trial explores if they work better together. For the first 28 days (Cycle 1), patients take ruxolitinib (10 mg twice daily). From Cycle 2, they add belumosudil (200 mg once or twice daily, depending on other medications) for 48 weeks (12 cycles) unless their condition worsens or side effects become intolerable. Follow-up visits occur 30 days and 6 months after treatment ends to check health status.\n\nThe study is non-randomized (all get the same treatment) and open-label (patients and doctors know the drugs used). It aims to see if this combination better controls cGvHD in patients where steroids failed. This could offer hope for better symptom management and improved quality of life for those with limited treatment options.",[27],"2026-06-09",{"date":102,"type":32},"2026-06-11",{"date":82,"type":20},{"date":105,"type":20},"2030-07",{"name":107,"class":39},"Dennis Kim",1,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":116,"sex":16,"minAge":72,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":108},"100534884","phase-3-safety-and-efficacy-of-iguratimod-in-the-treatment-of-chronic-gvhd-100534884","NCT06244628","Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD","Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n1. Patients aged ≥18 years who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT), regardless of gender.\n2. Those with persistent manifestations of chronic graft-versus-host disease (cGVHD) and suitable for systemic treatment.\n3. Previously received at least 1 but not more than 5 lines of systemic treatment for cGVHD.\n4. Corticosteroid therapy dose stable for the two weeks before screening; or, if taking prednisone or an equivalent dose of other corticosteroids at a dose \\>0.5mg\u002Fkg\u002Fday for four weeks, with ongoing cGVHD manifestations and no improvement; or, if two attempts to taper steroids to a lower dose have failed, and it is necessary to increase the prednisone dose to \\>0.25mg\u002Fkg\u002Fday or an equivalent dose.\n5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score: 0\\~1.\n6. Anticipated survival of more than 12 months.\n\n   General criteria:\n7. Serum pregnancy test negative for women of childbearing age during the screening period.\n8. Sexually active women of childbearing age participating in this study must agree to contraception during the trial and after the last dose of medication.\n\nExclusion Criteria:\n\n1. Patients who have received experimental treatment for systemic cGVHD within the 28 days prior to enrollment, which was effective and could completely alleviate immunosuppression.\n2. Blood cancer relapse (according to the corresponding criteria for relapse of the primary blood cancer) or post-transplant lymphoproliferative disease at the time of screening.\n\n   Laboratory tests:\n3. Absolute neutrophil count (ANC) \\\u003C1.5×10\\^9\u002FL (excluding GVHD as the cause).\n4. Platelet count \\\u003C50×10\\^9\u002FL (excluding GVHD as the cause).\n5. Alanine aminotransferase (ALT) \\>3 times the upper limit of normal (ULN), aspartate aminotransferase (AST) \\>3×ULN (excluding GVHD as the cause).\n6. Total bilirubin (TBIL) \\>1.5×ULN (excluding GVHD as the cause).\n7. Creatinine clearance CrCl \\\u003C60 mL\u002Fmin (Cockcroft-Gault formula).\n\n   General criteria:\n8. Pregnant or lactating women.\n9. History of serious illness or other evidence indicating a serious illness, or any other condition that the investigator believes may make the subject unsuitable for this study.\n\n   * History of severe cardiovascular disease \\[New York Heart Association (NYHA) functional class III or IV\\], including but not limited to ventricular arrhythmias requiring clinical intervention, uncontrolled hypertension (systolic blood pressure ≥160mmHg and\u002For diastolic blood pressure ≥100mmHg); within 6 months prior to enrollment, there is unstable angina, acute coronary syndrome, congestive heart failure, stroke, or other cardiovascular events of class III or above; at screening, NYHA functional class ≥II or left ventricular ejection fraction (LVEF) \\\u003C50% on echocardiography.\n   * Unable to take oral medications, with severe (NCI CTCAE v5.0 ≥ grade 3) chronic gastrointestinal dysfunction, the presence of malabsorption syndrome, or any other condition affecting gastrointestinal absorption.\n   * History of clear neurological or psychiatric disorders (including epilepsy or dementia), currently suffering from psychiatric disorders, or judged by the investigator to be non-compliant and unsuitable for participation in the study.\n   * History of other severe (NCI CTCAE v5.0 ≥ grade 3) systemic diseases, deemed unsuitable for participation in the clinical trial by the investigator.\n10. Other circumstances in which the investigator deems it inappropriate to participate in this study.",true,"60 Years",{"count":119,"type":20},20,[121],"PHASE3","This is a randomized, single-center phase 3 clinical trial without blinding. Iguratimod, as a rheumatoid arthritis medication, is used to treat autoimmune diseases such as Sjögren's syndrome. It has acceptable side effects, good clinical availability, and is cost-effective. The investigators plan to recruit participants for a clinical trial to evaluate the efficacy and safety of Iguratimod in the treatment of chronic GVHD.",[27],[125,27],"Iguratimod","2026-05-26",{"date":128,"type":32},"2026-05-27",{"date":130,"type":32},"2024-01-10",{"date":132,"type":20},"2028-12-31",{"name":134,"class":39},"Xuzhou Medical University",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":72,"maxAge":49,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":153,"locationsCount":108},"100612413","early-phase-1-a-clinical-study-evaluating-the-safety-and-efficacy-of-gt729-universal-cell-injection-in-the-treatment-of-refractory-or-relapsed-chronic-graft-versus-host-disease-cgvhd-100612413","NCT07253259","A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)","Inclusion Criteria:\n\n* Participants or their legal representatives voluntarily sign a written informed consent form, are willing and able to comply with the procedures of this study.\n* Aged 18 to 65 years old (inclusive) when signing the informed consent, regardless of gender.\n* Participants must meet the following criteria:\n\n  1. The subjects are allogeneic hematopoietic stem cell transplantation (alloHSCT) recipients with active chronic graft-versus-host disease (active cGVHD) requiring systemic immunosuppressive therapy.\n  2. The subjects are patients with refractory or relapsed active cGVHD after receiving at least two lines of systemic treatment.\n* The laboratory test results during the screening period must meet the following criteria (except for indicators related to the study disease):\n\n  1. Neutrophil count ≥ 1.0×10⁹\u002FL;\n  2. Hemoglobin ≥ 80g\u002FL; Platelet count ≥ 30×10⁹\u002FL;\n  3. Alanine transaminase ≤ 3×upper limit of normal (ULN); Aspartate transaminase ≤ 3×ULN; Total bilirubin (TBIL) \\\u003C 2×ULN;\n  4. Creatinine clearance rate ≥ 30 mL\u002Fmin.\n* Women of childbearing age must:\n\nAt the time of screening, as confirmed by the investigator, the result of the serum β-human chorionic gonadotropin (β-hCG) pregnancy test is negative.\n\nExclusion Criteria:\n\n* Evidence of recurrence of underlying malignant tumors or post-transplant lymphoproliferative disorder (PTLD) at the time of screening\n* Having a history of severe hypersensitivity or allergies\n* Suffering from the following heart diseases:\n\n  1. New York Heart Association (NYHA) Class III or IV congestive heart failure;\n  2. A myocardial infarction occurred or coronary artery bypass surgery was performed within 6 months before the screening period.\n* Participants with clinically significant bleeding symptoms or a clear bleeding tendency within the 6 months prior to screening;\n* Participants with severe underlying medical conditions at the time of screening;\n* Participants who have undergone major surgery within 8 weeks prior to screening or are scheduled to undergo surgery during the study period;\n* History of organ transplantation;\n* According to the investigator's judgment, there are circumstances that would prevent the participant from completing the entire trial, confuse the trial results, or make participation in the trial not in the best interest of the participant.",{"count":142,"type":20},36,[144],"EARLY_PHASE1","The goal of this clinical study is to evaluate the safety and efficacy of GT729 universal cell injection in the treatment of refractory or relapsed chronic graft-versus-host disease (cGVHD).",[27],"2026-04-13",{"date":149,"type":32},"2026-04-14",{"date":151,"type":32},"2025-12-18",{"date":132,"type":20},{"name":154,"class":155},"Grit Biotechnology","INDUSTRY",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":72,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":184},"100509905","observational-study-for-patients-at-risk-for-chronic-graft-versus-host-disease-100509905","NCT05919511","Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease","A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)","THRIVE","Inclusion Criteria:\n\n* Age ≥ 18 years inclusive at the time of signing the ICF\n* Allogeneic SCT 90 to 180 days prior to enrollment\n* Able to comprehend and willing to provide informed consent\n* Willing and able to complete participant-assessment questionnaires either alone or with minimal assistance from a caregiver and\u002For trained site personnel\n\nExclusion Criteria:\n\n* There are no exclusion criteria for this study",{"count":165,"type":20},1500,"OBSERVATIONAL","The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)",[27],[170,27,171,162,172,173,174],"chronic graft versus host disease","MA-GVHD-401","GVHD","chronic GVHD","allogenic stem cell transplant (alloSCT)","2026-03-20",{"date":177,"type":32},"2026-03-24",{"date":179,"type":32},"2023-08-01",{"date":181,"type":20},"2027-10-15",{"name":183,"class":155},"Incyte Corporation",32,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":72,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":21,"phases":195,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":4},"100629607","phase-1-gecacitinib-in-the-treatment-of-steroid-refractorydependent-chronic-graf-versus-host-disease-cgvhd-100629607","NCT07476872","Gecacitinib in the Treatment of Steroid-Refractory\u002FDependent Chronic Graf Versus Host Disease (cGVHD).","A Single-Arm, Open-Label, Single-Center Phase Ib\u002FIIa Clinical Study of Gecacitinib in the Treatment of Steroid-Refractory\u002FDependent Active Chronic Graf Versus Host Disease (cGVHD).","CONTINUUM-GVHD","Inclusion Criteria:\n\n1. Age ≥ 18 years, regardless of gender.\n2. Underlying hematologic malignancies or non-malignant disorders having received allogeneic hematopoietic stem cell transplantation.\n3. Diagnosis of active cGVHD according to the 2014 NIH consensus criteria, meeting the definition of steroid-refractory or steroid-dependent cGVHD. Prior lines of cGVHD therapy are not restricted. Definitions are as follows:\n\n   1. Steroid-refractory cGVHD is defined as meeting any of the following criteria: disease progression despite the use of prednisone ≥1 mg\u002Fkg\u002Fday (or equivalent dose of corticosteroids) for at least 1 week; OR, persistent disease symptoms with no improvement despite the use of prednisone ≥0.5 mg\u002Fkg\u002Fday or ≥1 mg\u002Fkg every other day (or equivalent dose of corticosteroids) for at least 4 weeks.\n   2. Steroid-dependent cGVHD is defined as the requirement for a maintenance dose of prednisone \\>0.25 mg\u002Fkg\u002Fday or \\>0.5 mg\u002Fkg every other day (or equivalent dose of corticosteroids) to prevent disease flare or progression, and failure to successfully taper the dose to a lower level in at least 2 separate attempts spaced ≥8 weeks apart.\n4. Platelet count ≥50 × 10⁹\u002FL and absolute neutrophil count (ANC) ≥0.5 × 10⁹\u002FL, without the use of colony-stimulating factors, androgens, erythropoietin, thrombopoietin, or platelet transfusion within 7 days prior to screening.\n5. Adequate major organ function, defined as meeting the following criteria: ALT and AST ≤ 2.5 × upper limit of normal (ULN); direct and total bilirubin ≤ 2.0 × ULN; serum creatinine ≤ 1.5 × ULN.\n6. Stable underlying disease without evidence of progression or relapse.\n7. Karnofsky Performance Status (KPS) ≥ 60%.\n8. Voluntarily participate in this study, provide signed informed consent, demonstrate good compliance, and be able to adhere to the study and follow-up procedures\n\nExclusion Criteria:\n\n1. Post-transplant lymphoproliferative disorder, or loss of full donor chimerism due to other reasons.\n2. Previous use of, or current treatment with, other JAK inhibitors at the time of screening.\n3. History or presence of major diseases or clinically significant organ dysfunction that cannot be adequately controlled by treatment and may interfere with study completion:\n\n   1. Congestive heart failure of New York Heart Association (NYHA) class III-IV, or documented history of diastolic or systolic dysfunction (e.g., left ventricular ejection fraction \\\u003C40% by echocardiography), or uncontrolled\u002Funstable angina or myocardial infarction.\n   2. Uncontrolled diabetes (blood glucose \\>250 mg\u002FdL or \\>13.9 mmol\u002FL).\n   3. Hypertension that cannot be adequately controlled to systolic blood pressure \\\u003C160 mmHg and diastolic blood pressure \\\u003C100 mmHg despite combination antihypertensive therapy.\n   4. Peripheral neuropathy (Grade 2 or higher per NCI-CTCAE v5.0 criteria).\n4. Patients with any uncontrolled bacterial, viral, or fungal infection.\n5. Positive for HIV at screening, or active hepatitis B virus infection (HBsAg positive and HBV-DNA positive or above the upper limit of normal), or positive for HCV antibody with detectable HCV-RNA.\n6. History of tuberculosis or positive interferon-γ release assay at screening.\n7. Concurrent use of strong CYP3A4 inhibitors.\n8. History of progressive multifocal leukoencephalopathy.\n9. Known or suspected hypersensitivity to Gecacitinib hydrochloride, drugs of the same class, or any of their excipients.\n10. Pregnant or lactating women, or patients unwilling to use effective contraception during Gecacitinib treatment and for 1 week after the last dose.\n11. Inability to swallow oral tablets.",{"count":194,"type":20},33,[75,23],"This study aims to evaluate the safety and efficacy of Gecacitinib in patients with steroid-refractory\u002Fdependent active chronic graft versus host disease (cGVHD).",[27,198],"HSCT",[27,200,198],"Gecacitinib","2026-03-12",{"date":203,"type":32},"2026-03-17",{"date":205,"type":20},"2026-03-16",{"date":207,"type":20},"2028-11-01",{"name":209,"class":39},"Institute of Hematology & Blood Diseases Hospital, China",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":16,"minAge":72,"maxAge":49,"enrollmentInfo":217,"targetDuration":4,"studyType":21,"phases":219,"briefSummary":220,"conditions":221,"keywords":225,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":108},"100611857","phase-2-bpc2001-for-the-prevention-of-acute-graft-versus-host-disease-following-haploidentical-stem-cell-transplantation-100611857","NCT07246031","BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation","An Open-Label, Single-Arm, Phase Ⅱb Clinical Study of BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation","Inclusion Criteria:\n\n1. Male or female ages ≥18 and ≤ 65 years.\n2. Before the start of the trial, the subject or his\u002Fher guardian is sufficient to understand and voluntarily sign the written informed consent form (ICF).\n3. Subjects have a hematologic malignancy as defined below and are considered candidates for haplo-SCT:\n\n   1. Acute leukemia with morphologic complete remission (acute myelogenous leukemia \\[AML\\] or acute lymphoblastic leukemia \\[ALL\\]);\n   2. Myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), or myeloproliferative neoplasm (MPN) with \\\u003C 10% blasts in the bone marrow.\n4. Organ function tolerated for transplantation:\n\n   1. Cardiac function: Left ventricular ejection fraction at rest ≥ 45%;\n   2. Liver function: Total bilirubin \\\u003C 1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C 2.5 × ULN. Subjects who have been diagnosed with Gilbert's syndrome or malignant disease involvement are allowed to have a total bilirubin value \\> 1.5 × ULN;\n   3. Serum creatine \\\u003C 2 mg\u002FdL or estimated creatinine clearance \\> 50 mL\u002Fmin calculated using the Cockcroft-Gault equation；\n   4. Pulmonary function tests (PFTs): diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) and\u002For forced expiratory volume in 1 second (FEV1) ≥ 50%.\n5. Subject is suitable for myeloablative haplotype related donor transplant.\n6. Subject is suitable for receiving first alloHSCT.\n7. The transplant donor must meet the following criteria:\n\n   1. Donor ages \\> 30 years; If the donor ages is equal to or less than 30 years, the donor should be female for male subject;\n   2. High-resolution typing of human leukocyte antigen (HLA)-A, -B, -C, DR, and DQ are matched at least 5\u002F10;\n   3. Meet the criteria for peripheral blood stem cell (PBSC) donation;\n   4. Donor's specific antibodies are negative, \\\u003C2,000 MFI.\n8. Source of allografts: using G-CSF as the mobilizing agent to mobilize PBSC transplant; bone marrow or cord blood is not allowed.\n9. Karnofsky Performance Status (KPS) score ≥ 60 points.\n10. Is a Candidate for anti-GvHD prophylaxis, including ATG, calcineurin inhibitor (CsA or tacrolimus \\[FK 506\\]) in combination with MTX and MMF.\n11. Female subjects of childbearing potential must have a negative serum pregnancy test prior to enrollment and must have agreed to use a double barrier method of contraception from the time of signing the ICF to 90 days after the last dose of investigational drug.\n12. Male subjects must agree to use effective contraception from the time of signing the ICF to 90 days after the last dose of investigational drug.\n\nExclusion Criteria:\n\nAny subjects who meet any of the following criteria will be excluded from study entry:\n\n1. Has had any other prior organ transplantation.\n2. Planned use of any additional or alternative drugs for GvHD prophylaxis than listed in the inclusion criteria.\n3. Has had received an investigational drug within 4 half-lives or within 14 days prior to HSCT, whichever is longer; or plans to participate in another clinical study prior to completion of all scheduled evaluations in this clinical study.\n4. Has other malignancies that are not controlled.\n5. Has evidence of active central nervous system (CNS) disease.\n6. Patients with uncontrolled active bacterial, viral, or fungal infections.\n7. Known history of human immunodeficiency virus (HIV) or positive HIV antibody test.\n8. Hepatitis B virus surface antigen (HBsAg) or hepatitis B virus core antibody (HBcAb) is positive, and the hepatitis B virus (HBV) DNA in peripheral blood is above the limit of quantification; or hepatitis C virus (HCV) antibody and peripheral HCV RNA are positive; or the syphilis TRUST test is positive.\n9. Pregnant or lactating females.\n10. Has undergone major surgery within 1 month prior to the first dose of investigational drug.\n11. In the opinion of the investigator, the subject has any other medical condition that renders the subject unsuitable for participation in the study.\n12. Has a history of uncontrolled autoimmune disease or on active treatment.\n13. Vaccinated with live or attenuated vaccine within 4 weeks prior to the first dose of investigational drug.\n14. History of myocardial infarction, unstable angina, acute coronary syndrome, congestive heart failure (New York Heart Society classification ≥ class Ⅲ), or clinically significant arrhythmia within 6 months prior to receiving the investigational drug.\n15. Plan to use prophylaxis donor lymphocyte infusion (DLI) therapy.\n16. The transplant donor is the subject's mother or collateral relative.",{"count":218,"type":20},50,[23],"A Phase IIb open label study evaluates the safety and efficacy of repeat doses of BPC2001 in combination with standard of care treatment for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following Haploidentical Stem Cell Transplantation (Haplo-SCT).",[222,223,224,27],"Graft -Versus-host-disease","aGVHD","Haploidentical Stem Cell Transplantation",[226,227,228,229,230],"aGvHD","Haplo-SCT","BPC2001","BioPhoenix","KRN-7000","2025-11-20",{"date":233,"type":32},"2025-11-24",{"date":235,"type":32},"2025-10-29",{"date":237,"type":20},"2028-02-28",{"name":239,"class":155},"BioPhoenix Co., Ltd.",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":72,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":21,"phases":250,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":108},"100586808","early-phase-1-treatment-of-refractory-cgvhd-by-donor-derived-treg-cell-injection-combined-with-recombinant-human-interleukin-2-100586808","NCT06920199","Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2","Clinical Study to Evaluate the Safety and Efficacy of Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2 in the Treatment of Refractory cGVHD Subjects","Inclusion Criteria:\n\n* Subjects aged 18-70 years old, male or female;\n* The subjects had received allo-HSCT, including cord blood transplantation;\n* TSubjects with moderate\u002Fsevere cGVHD that meets the NIH diagnostic criteria (031) for steroid dependence or resistance, meeting one of the following:\n\n  1. There was no improvement in cGVHD in initial treatment patients treated with \\> 0.5mg\u002Fkg\u002F day or 1 mg\u002Fkg\u002F day every other day for at least 4 weeks;\n  2. Steroid dependence: predtisone dose \\> 0.25 mg\u002Fkg\u002Fd or \\> 0.5 mg\u002Fkg\u002Fqod cGVHD relapse or progression; cGVHD recurred after two attempts to gradually reduce prednisone dose at an interval of at least 8 weeks, with prednisone dose \\> 0.25 mg\u002Fkg\u002Fday to be maintained.\n* Prednisone dose \\> 0.25 mg\u002Fkg\u002Fd for more than 4 weeks; Subjects must maintain a stable prednisone dose for 4 weeks prior to the first Treg cell infusion and not increase or discontinue other immunosuppressants (including cyclosporine, tacrolimus, and sirolimus);\n* The ECOG score of the subjects was 0-2;\n* the expected survival of the subject is more than 3 months;\n* Liver, kidney, heart and lung function meet the following requirements (except liver and kidney dysfunction caused by cGVHD) :\n\n  1. Creatinine clearance (calculated by Cockcroft Gault formula) ≥60 mL\u002Fmin;\n  2. Cardiac ejection fraction greater than 50%, no clinically significant electrocardiogram changes;\n  3. Forced expiratory volume (FEV1) in the first second of baseline lung function ≥50%, and FEV1 decline caused by cGVHD could be included;\n  4. Total bilirubin ≤2.0ULN; ALT and AST≤3ULN, ALT and AST increases caused by cGVHD could be included in the group.\n* Hematopoietic function: neutrophils \\>1×10\\^9\u002FL, platelets \\>25×10\\^9\u002FL; Supportive treatments such as platelet transfusion and other cytokines are excluded.\n* The subject or the subject's guardian can understand this experiment and has signed the informed consent.\n* Donor age 14-70 years old, male or female;\n* The ECOG score of the donor is 0-1;\n* The donor must be a hematopoietic stem cell donor who underwent allo-HSCT prior to the subject;\n* Female donors must test negative for serum or urine beta-human chorionic gonadotropin (HCG) within 3 weeks of blood collection;\n* The donor can establish the necessary venous access for collection, without the contraindication of white blood cell collection; If peripheral venous leukocyte collection is insufficient, be willing to insert a central catheter; (15) The donor agrees to donate and signs a consent form.\n\nExclusion Criteria:\n\n* Subjects had a recurrence of primary malignant disease before receiving Treg treatment;\n* The subjects had persistent, recurrent or delayed aGVHD;\n* Continuous use of prednisone \\>1 mg\u002Fkg\u002Fday is required;\n* The severity of the subject's cGVHD cannot be assessed by physical examination or laboratory examination;\n* overlap syndrome；\n* The subjects had major organ (cardio-cerebrovascular, pulmonary) dysfunction not caused by cGVHD, and had previous (within 3 months) gastrointestinal active bleeding; History of uncontrolled hypertension or hypertensive crisis or hypertensive encephalopathy, history or evidence of significant cardiovascular and cerebrovascular risk, including any of the following conditions: congestive heart failure, unstable angina pectoris, clinically significant arrhythmias (e.g., ventricular fibrillation, ventricular tachycardia, etc.); History of arterial thrombosis (such as stroke, transient ischemic attack) within the last 3 months; A history of symptomatic deep vein thrombosis, pulmonary embolism, or coronary angiogenesis, defibrillation, or any clinically relevant complication or disease within the last 6 months that could pose a risk to subject safety or interfere with study evaluation, procedure, or completion;\n* The subjects are hemodialysis patients;\n* The subject or donor has an active, uncontrolled bacterial, viral, or fungal infection that requires treatment；\n* The subjects are pregnant or lactating women; Subjects who plan to become pregnant during the post-transfusion study, or within 1 year of completion or withdrawal from the study;\n* Participants who had received IL-2 therapy or drug therapy targeting IL-2 within 4 weeks prior to enrollment；\n* Received DLI treatment within 100 days before enrollment;\n* Received CAR-T or similar engineered cell therapy within 100 days prior to enrollment;\n* Had received new cGVHD therapies (including imatinib, BTK inhibitors, rituximab and other immunosuppressants) within 4 weeks before enrollment after transplantation;\n* Have a history of microvascular diseases such as TMA, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, etc；\n* Subjects with poor IL-2 treatment compliance;\n* Participants who participated in other CGVHD-related clinical studies within 4 weeks prior to enrollment;\n* Subjects who are known to be allergic to any component of Treg cell injection;\n* Any situation that the investigator believes would compromise the safety of the subject or interfere with the study purpose, or that the investigator considers it inappropriate to participate in the study;\n* Having a medical condition that affects the signing of written informed consent or the inability to follow study procedures; Unwilling or unable to comply with research requirements;\n* The donor was a pregnant woman.","70 Years",{"count":249,"type":20},18,[144],"This study is a single-arm, open-label, dose-escalation clinical trial to evaluate the safety, tolerability, changes and persistence of peripheral blood Treg cells, and pharmacodynamic characteristics of donor-derived Treg cell injection combined with recombinant human interleukin-2 in treating subjects with refractory cGVHD，and to preliminarily observe the efficacy of the study drugs in subjects with refractory cGVHD.",[27],[254,255],"Steroid dependence","Refractory cGVHD","2025-09-28",{"date":258,"type":32},"2025-09-30",{"date":260,"type":32},"2025-06-14",{"date":262,"type":20},"2027-09-15",{"name":264,"class":39},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine"]